• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed announces new Impella device, plan for Japan | Wall Street Beat

Abiomed announces new Impella device, plan for Japan | Wall Street Beat

December 19, 2011 By MassDevice staff

MassDevice.com Wall Street Beat

Amid celebrating the first human use of its Symphony implantable heart pump for chronic heart failure patients, Abiomed (NSDQ:ABMD) unveiled a new ventricular assist device for its flagship Impella line of heart pumps.

Announced at the company’s annual investors’ day in New York, the new device is slated to hit the market some time next summer. Abiomed also has its sights set on entering the Japanese market in 2013.

The new Impella cVAD device is a "paradigm shift," according to Abiomed CTO Thorsten Siess. Unlike other VADS which are surgically implanted, the Abiomed product is inserted via catheter.

Sign up to get our free newsletters delivered right to your inbox

"We know that the cath lab may require, in certain cases, prolonged, profound support beyond what we can offer today," Seiss said.

Abiomed also has plans for the Land of the Rising Sun, where the Impella has been listed as a "critical need" device by major cardiac societies. Because there is virtually no use of heart transplants or VAD devices in Japan, a device like the Impella has an extra leg up there, according to the company.

Abbott, BSX facing new stent rival?
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) could be up against a new competitor in the $6.1 billion global stents market, according to Forbes: InspireMD (OTC:NSPR) and its MGuard micro-mesh stent. The device has won CE Mark approval in the European Union and is on the market in 40 countries, according to the magazine, which notes that former Celgene (NSDQ:CELG) chairman Sol Barer is now InspireMD’s chairman. Read more 

Baxter closes $500M bond deal

Baxter International (NYSE:BAX) closed a $500 million sale of 1.85% coupon, 5-year bonds priced to yield 1.862%, according to Dow Jones Newswire. Read more 

Analysts’ ups & downs

  • Abiomed (NSDQ:ABMD): Rodman & Renshaw downgrades to "market underperform" from "market "perform," sets $13-per-share price target.
  • Amgen (NSDQ:AMGN): Goldman Sachs upgrades to "sell" from "neutral," sets $57 price target.
  • Baxter International (NYSE:BAX): Goldman Sachs downgrades to "buy" from "conviction buy."
  • Covidien (NYSE:COV): Goldman Sachs boosts price target to $53, sets "buy" rating; Moody’s Investors Service reiterates "Baa1" rating, lowers outlook from "positive" to "stable."
  • Thoratec (NSDQ:THOR): Goldman Sachs establishes coverage at "neutral," sets $33 price target.

Filed Under: News Well, Structural Heart, Wall Street Beat Tagged With: Abbott, Abiomed, Amgen, Baxter, Boston Scientific, Covidien, Stent Wars, Thoratec Corp.

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy